Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -106.79% is 44% above its 5-year average of -190.82%, near the high end of its 5-year range (-605.22%–20.44%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.70% above its 12-month average of -115.69%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -106.79%.
RETURN ON EQUITY (ROE)
-106.79%
RETURN ON EQUITY (ROE) AVG TTM
-115.69%
RETURN ON EQUITY (ROE) AVG 3Y
-133.10%
RETURN ON EQUITY (ROE) AVG 5Y
-190.82%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.70%
CURRENT VS 3Y AVG
+19.76%
CURRENT VS 5Y AVG
+44.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.78%
median of 740 covered companies
CURRENT VS SECTOR MEDIAN
-155.57%
vs the sector median at left
Revelation Biosciences, Inc.
Market Cap
$3.05M
Return on Equity (ROE)
-106.79%
TTM Avg
-115.69%
3Y Avg
-133.10%
5Y Avg
-190.82%
Market Cap
$3.04M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
Market Cap
$3.01M
Return on Equity (ROE)
-365.43%
TTM Avg
-2048.73%
3Y Avg
-1082.52%
5Y Avg
-614.77%
Market Cap
$3.13M
Return on Equity (ROE)
-141.90%
TTM Avg
-194.17%
3Y Avg
-143.89%
5Y Avg
-113.05%
Market Cap
$3.16M
Return on Equity (ROE)
120.45%
TTM Avg
927.43%
3Y Avg
433.61%
5Y Avg
340.10%
Market Cap
$3.25M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
Market Cap
$3.27M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$2.77M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
Market Cap
$2.84M
Return on Equity (ROE)
-6.54%
TTM Avg
-12.86%
3Y Avg
-15.03%
5Y Avg
-0.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $3.05M | -106.79% | -115.69% | -133.10% | -190.82% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | N/A | -236.13% | -104.67% | -48.54% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.01M | -365.43% | -2048.73% | -1082.52% | -614.77% |
| IceCure Medical Ltd (ICCM)vs › | $3.13M | -141.90% | -194.17% | -143.89% | -113.05% |
| MBody AI Ltd. (MBAI)vs › | $3.16M | 120.45% | 927.43% | 433.61% | 340.10% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | -40.75% | -35.89% | -218.64% | -156.11% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | -133.43% | -203.84% | -174.81% | -140.61% |
| iSpecimen Inc. (ISPC)vs › | $2.77M | -657.69% | -358.53% | -220.37% | -149.08% |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.84M | -6.54% | -12.86% | -15.03% | -0.76% |
| Moolec Science S.A. (MLEC)vs › | $3.46M | -89.85% | 30.83% | -183.24% | -146.59% |
ROE
-106.8%
ROA
-86.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -106.79% |
| 2026-03-31 | -76.00% |
| 2025-12-31 | -100.59% |
| 2025-09-30 | -73.88% |
| 2025-06-30 | -221.20% |
| 2025-03-31 | -500.15% |
| 2024-12-31 | -319.40% |
| 2024-09-30 | -580.33% |
| 2024-03-31 | -94.59% |
| 2023-12-31 | -1.81% |
| 2023-09-30 | 9.92% |
| 2023-06-30 | 20.44% |
| 2023-03-31 | 19.43% |
| 2022-09-30 | -605.22% |
| 2021-09-30 | -301.53% |
| 2021-06-30 | -121.45% |
| 2021-03-31 | -8.22% |
| 2020-12-31 | -4.52% |
